Drug Approval | May 08, 2024
USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
This acquisition enables MTD to open new, strategic markets
Executes the first project for developing and manufacturing a novel anticancer mAb
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The investment will catalyse various components of the IndiaAI Mission
Subscribe To Our Newsletter & Stay Updated
